Comparison of early treatment outcomes rendered in three different types of malocclusions.

OBJECTIVE: To evaluate the outcome of early treatment in Class I, II, and III malocclusions based on the reduction of weighted Peer Assessment Rating (PAR) scores. MATERIALS AND METHODS: Two hundred thirty subjects (female = 105; male = 125) selected from 400 cases were divided into three groups based on their malocclusions (Class I, II, and III). The PAR index was evaluated prior to early treatment (T0), at the end of phase I (T1), and after completion of phase II therapy (T2). The reliability of overall PAR scores was assessed by Bland-Altman plot and intraclass correlation coefficient. The starting age, total weighted PAR scores and their changes after phase I and II treatments, treatment time, and the percentage of correction in the three different malocclusions were assessed by repeated-measures analysis of variance with post hoc analysis. The level of significance was set at P < .05. RESULTS: More than 30% reduction of the weighted PAR scores and less than 10 points of the remaining weighted PAR scores were observed in all malocclusion groups at T1. The Class III group had the highest percentage of correction during phase I treatment. CONCLUSIONS: Early treatment effectively reduced the complexity of Class I, II, and III malocclusions and accounted for 57%, 64%, and 76% of the total correction, respectively, after phase I treatment, as indicated by an overall reduction in weighted PAR scores. The Class III group responded most favorably to early treatment followed by the Class II group.

Isolated heart and liver transplant recipients are at low risk for polyomavirus BKV nephropathy.

BACKGROUND: BKV infection and nephropathy is a significant cause of allograft dysfunction in kidney transplantation. BKV viremia, rather than viruria, corresponds to BKV nephropathy. The prevalence of BKV viremia in non-renal solid organ transplants has not been systematically evaluated. METHODS: We determined prevalence of BKV viremia in kidney, combined kidney-heart, kidney-liver, kidney-pancreas, kidney-heart-liver, and heart and liver transplant recipients using BKV-PCR. RESULTS: Seven out of 173 (4%) kidney transplant recipients had BKV viremia, with BKV>2 x 10(5) copies/mL in 6/7 and 1.9 x 10(3) in the remaining one patient. BKV viremia was not found in 24 heart transplant recipients, whereas 1/37 (2.7%) liver transplants showed low copy numbers (< or =10(3)). BKV-PCR< or =10(3) copies/mL were also found in one of each combined kidney-heart and kidney-liver transplant recipients. BKV nephropathy was proven by biopsy in 4/6 patients with high BKV viral loads. All six patients showed renal dysfunction, requiring reduction in immunosuppression and antiviral therapy. All four patients with low BKV viral loads (1.9 x 10(3) or < or =10(3)) showed stable renal function after reduction of immunosuppression or no treatment, respectively. CONCLUSION: Higher BKV levels in plasma are associated with renal dysfunction. Kidney transplant recipients are at high risk compared with recipients of isolated heart or liver allografts, for development of BKV nephropathy.